Pioglitazone Hydrochloride

ApprovedSmall molecule

Pioglitazone Hydrochloride is one of 207 small molecule programs targeting Oral leukoplakia. It is currently in Approved.

Indications

Total Trials

Active Trials

206

Competitors

Pipeline

Status by Indication[3][1]

Indication

Oral LeukoplakiaActive, not recruiting

Type 2 Diabetes MellitusActive, not recruiting

Myocardial InfarctionActive, not recruiting

Septic ShockActive, not recruiting

Non-Small Cell Lung CancerActive, not recruiting

Pancreatic CancerActive, not recruiting

Type 2 DiabetesActive, not recruiting

AsthmaActive, not recruiting

Oral LeukoplakiaPhase 2

Active, not recruiting

Type 2 Diabetes MellitusPhase 3

Active, not recruiting

Myocardial InfarctionApproved

Active, not recruiting

Septic ShockPhase 1/Phase 2

Active, not recruiting

Non-Small Cell Lung CancerPhase 2

Active, not recruiting

Pancreatic CancerPhase 1

Active, not recruiting

Type 2 DiabetesPhase 3

Active, not recruiting

AsthmaPhase 2

Active, not recruiting

Competition

Competitive Landscape

1639 competitors in Non-Small Cell Lung Cancer

#DrugCompanyPhaseTrials

Pioglitazone Hydrochloride

Merck & Co.

Approved

1 2

PORTRAZZA

Eli Lilly

Preclinical

8 3

Lenvima

Eisai

Preclinical

6 4

Imjudo

AstraZeneca

Preclinical

5 5

Gilotrif

Boehringer Ingelheim

Preclinical

12 6

Aqupla

Jiangsu Simcere Pharmaceutical Co., Ltd.

Preclinical

—7

Vibramycin

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Treatment

1 9

Vidaza

Bristol-Myers Squibb

Preclinical

1 10

Huaier Granule

QQidong Gaitianli Medicines Co., Ltd

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Type 2 Diabetes Mellitus2 trials

Efficacy Study of Pioglitazone and Metformin and Association Between Pioglitazone Response and Peroxisome Proliferator-activated Receptor Gamma Gene Variants in Bangladeshi Type 2 Diabetes Mellitus Subjects

Completed·—·Phase 4·NCT01589445·77 enrolled

MK0431 and Pioglitazone Co-Administration Factorial Study in Patients With Type 2 Diabetes Mellitus (0431-102 AM2)

Completed· Merck & Co. logo

Merck & Co.·Phase 3·NCT00722371·1,615 enrolled

Asthma1 trial

Pioglitazone Hydrochloride (Actos(Registered Trademark)) to Treat Asthma

Withdrawn·NNational Heart, Lung, and Blood Institute (NHLBI)·Phase 2·NCT00604578

Oral leukoplakia1 trial

Pioglitazone Hydrochloride in Preventing Head and Neck Cancer in Patients With Oral Leukoplakia

Completed·NNational Cancer Institute (NCI)·Phase 2·NCT00099021·21 enrolled

Pancreatic Cancer1 trial

Pioglitazone as Second-Line in Patients With Metastatic Pancreatic Cancer After Treatment With Gemcitabine

Terminated·UUniversity of Texas Southwestern Medical Center·Phase 1·NCT00867126·6 enrolled

Myocardial Infarction1 trial

The Effect of Sitagliptin, Pioglitazone and Dapagliflozine on Myocardial Infarction in Diabetic Rats

Completed·—·Phase 4·NCT07083232·50 enrolled

7 more indications

Non-Small Cell Lung Cancer1 trial

Pioglitazone Hydrochloride in Treating Patients With Stage IA-IIIA Non-small Cell Lung Cancer

Terminated·NNational Cancer Institute (NCI)·Phase 2·NCT01342770·6 enrolled

Premalignant Lesion1 trial

Pioglitazone for Oral Premalignant Lesions

Terminated·NNational Cancer Institute (NCI)·Phase 2·NCT00951379·52 enrolled

Septic Shock1 trial

Pharmacokinetic and Biomarker Study of Pioglitazone in Adolescents With Severe Sepsis and Septic Shock

Completed·—·Phase 1/2·NCT01352182·12 enrolled

Single Dose1 trial

A PHASE 1, OPEN-LABEL, CROSS-OVER, FIXED SEQUENCE STUDY TO EVALUATE THE EFFECT OF MULTIPLE DOSES OF DS-1971A ON THE SINGLE DOSE PHARMACOKINETICS OF PROBE SUBSTRATES FOR CYP2B6, CYP2C8, CYP2C9, CYP2C19 AND CYP3A4 ENZYMES IN HEALTHY MALE AND FEMALE SUBJECTS

Completed· Daiichi Sankyo logo

Daiichi Sankyo·Phase 1·NCT02473627·18 enrolled

Type 2 Diabetes1 trial

Efficacy and Safety of Dapagliflozin in Combination With Glimepiride (a Sulphonylurea) in Type 2 Diabetes Patients

Completed· AstraZeneca logo

AstraZeneca·Phase 3·NCT00680745·597 enrolled

Tics1 trial

A Study to Characterize the Effect on the Pharmacokinetics of ASP1941 and Pioglitazone Hydrochloride When Given Together to Healthy Subjects

Completed· Astellas logo

Astellas·Phase 1·NCT01088919·64 enrolled

Unspecified2 trials

Study of Changes in Hepatic Fat Following Administration of MK-4074 and Pioglitazone Hydrochloride (MK-4074-008)

Completed· Merck & Co. logo

Merck & Co.·Phase 1·NCT01431521·31 enrolled

Study in Healthy Subjects to Determine the Effect of Relacorilant on Exposure to Probe Substrates for Cytochrome P450s

Completed·CCorcept Therapeutics·Phase 1·NCT03457597·27 enrolled

Sources

References

[1]
ClinicalTrials.gov — 14 trial records for Pioglitazone Hydrochloride. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Pioglitazone Hydrochloride compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Pioglitazone Hydrochloride. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Merck & Co. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Approved[1]
Company: Merck & Co.

Pioglitazone Hydrochloride

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Type 2 Diabetes Mellitus2 trials

Asthma1 trial

Oral leukoplakia1 trial

Pancreatic Cancer1 trial

Myocardial Infarction1 trial

Non-Small Cell Lung Cancer1 trial

Premalignant Lesion1 trial

Septic Shock1 trial

Single Dose1 trial

Type 2 Diabetes1 trial

Tics1 trial

Unspecified2 trials

References

Drug Info

Quick Facts

Related News